Results 161 to 170 of about 198,039 (308)

Supplementary Data 1 from Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial

, 2023
Espen B. Ellingsen, Steven O’Day, Artur Mezheyeuski, Agnieszka Gromadka, Trevor Clancy, Timothy S. Kristedja, Mohammed Milhem, Yousef Zakharia   +7 more
openalex   +2 more sources

Complete Response unter Pembrolizumab-Therapie

, 2022
David Leffers, Christian Idel, Karl‐Ludwig Bruchhage   +2 more
openalex   +1 more source

Biomarker‐based long‐term safety and efficacy of PD‐1/PD‐L1 inhibitors combined with chemotherapy in advanced gastroesophageal carcinomas: A systematic review and meta‐analysis

Precision Medical Sciences, EarlyView.
This graphical abstract concisely encapsulates the principal findings of the meta‐analysis, emphasizing the notable survival advantages of PD‐1/PD‐L1 inhibitors in conjunction with chemotherapy for advanced gastroesophageal tumors. The visual presentation briefly defines the study's history, methodologies, results, and conclusions, while highlighting ...
Muhammad Ahsan, Muhammad Javaid Umer, Rath Shree, Jan Qureshi Ahmar, Ahmad Khan Mudassir, Masood Salman, Muhammad Hassan, Hayyat Omna, Iqbal Javed, Asraf Hussain   +9 more
wiley   +1 more source

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

Precision Radiation Oncology, EarlyView.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song, Lei Wang, Guopeng Zhao, Song Tan, Xin Liu, Xinghua Li   +5 more
wiley   +1 more source

Slowly Progressive Secondary Adrenal Insufficiency Due to Pembrolizumab Administration in a Patient With a History of Pituitary Neuroendocrine Tumor [PDF]

Hiroyuki Ueda, Yukari Fujita, Kosuke Mukai, Kazuyuki Miyashita, Junji Kozawa, Hitoshi Nishizawa, Iichiro Shimomura   +6 more
openalex   +1 more source

Fatal Pembrolizumab‐Induced Stevens‐Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Advanced Lung Adenocarcinoma

The Kaohsiung Journal of Medical Sciences, EarlyView.
Po‐Chih Chang, Ting‐Wei Chang, Chia‐Yu Kuo, Yi‐Zhe Wu   +3 more
wiley   +1 more source

Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High‐Risk Metastatic Hormone‐Naïve Prostate Cancer: Results From a 3‐Year Interim Analysis of the J‐ROCK Study

The Prostate, EarlyView.
ABSTRACT Introduction In real‐world practice in Japan, standard treatment for metastatic hormone‐naïve prostate cancer (mHNPC) is androgen deprivation therapy (ADT), administered as monotherapy, combined androgen blockade (CAB), ADT plus androgen receptor pathway inhibitors (ARPIs), or ADT plus docetaxel.
Atsushi Mizokami, Rikiya Matsumoto, Hideaki Miyake, Hiroji Uemura, Hirotsugu Uemura, Satoru Kawakami, Kazuyoshi Nakamura, Shigekatsu Maekawa, Hiroaki Tsuchiya, Sachie Okazaki, Eri Adachi, Ryo Yano, Yohei Tajima, Kiyohide Fujimoto, Hideyasu Matsuyama   +14 more
wiley   +1 more source

060 Lichenoid drug reaction and pyoderma gangrenosum induced by pembrolizumab therapy: A case report and review of literature [PDF]

D. Badin, Kate Bradley, Alasdair Hotston Moore, Jamie Karch, Islam Elbayoumi Salem, Brian Simmons   +5 more
openalex   +1 more source

Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma [PDF]

, 2021
E. Paul, Gerasimos Konidaris, Shannon Cope, Chieh-I Chen, Sam Keeping, Yingxin Xu, Kokuvi Atsou, Dieter Ayers, Patricia Guyot, Medha Sasané, Ali Mojebi, Andreas Kuznik   +11 more
openalex   +1 more source

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis

The Prostate, EarlyView.
ABSTRACT Background In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune ...
Tomoya Hatayama, Yohei Sekino, Go Kobayashi, Kazuma Yukihiro, Yoshinori Nakano, Shinsaku Tasaka, Naofumi Nomura, Yuki Kohada, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +16 more
wiley   +1 more source